HitGen Inc. (SHA:688222)
34.90
+0.25 (0.72%)
At close: Nov 17, 2026
HitGen Revenue
HitGen had revenue of 204.00M CNY in the quarter ending September 30, 2026, with 42.88% growth. This brings the company's total for the last twelve months to 705.76M, up 41.57% year-over-year. In the year 2025, HitGen had annual revenue of 525.57M with 23.09% growth. That makes HitGen the 22,282nd largest company in the world by revenue and 4,071st in China.
Revenue (ttm)
705.76M
Revenue Growth
+41.57%
P/S Ratio
19.70
Revenue / Employee
999.66K
Employees
706
Market Cap
14.00B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full HitGen breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 525.57M | 98.58M | 23.09% |
| Dec 31, 2024 | 426.99M | 55.66M | 14.99% |
| Dec 31, 2023 | 371.32M | 41.67M | 12.64% |
| Dec 31, 2022 | 329.65M | 18.59M | 5.98% |
| Dec 31, 2021 | 311.06M | 67.46M | 27.69% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Yili Chuanning Biotechnology | 4.06B |
| Xiamen Amoytop Biotech | 3.95B |
| Anhui Anke Biotechnology (Group) | 2.34B |
| Jinyu Bio-technology | 1.60B |
| BrightGene Bio-Medical Technology | 1.34B |
| Sinocelltech Group | 1.14B |
| Acrobiosystems | 1.03B |
| GemPharmatech | 941.80M |